**Equality Questionnaire Northern Ireland Arrangements for Assessing Applicability of NICE Guidance to the HSC Sector**

**Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy**

|  |
| --- |
| Is the NICE guidance likely to have an adverse impact on any of the nine equality groups identified under Section 75 of the Northern Ireland Act 1998? If so, please describe any such impact. |
| Are you aware of any indication or evidence, qualitative or quantitative, that the NICE guidance may have an adverse impact on equality of opportunity or good relations? If so please give details of any such evidence. |
| Does the NICE guidance afford an opportunity to better promote equality of opportunity or good relations? If so, how? |
| Are there any aspects of the NICE guidance where potential human rights violations may occur? |
| Name:  Organisation:  Please return to: [sgu-niceguidance@dhsspsni.gov.uk](mailto:sgu-niceguidance@dhsspsni.gov.uk) |

**This Information will be used to inform the Equality Screening.**